AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|
18.5 C
New York
Friday, October 16, 2026

Tag: therapy

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings more than 25 years...

Saving Heart Muscle After a Heart Attack: Nature Reports PeriFlow’s First-in-Class Capillary-Selective Vasodilator

PeriFlow Therapeutics is advancing CLN-2501, a first-in-class drug candidate designed to restore capillary blood flow after Acute Myocardial Infarction by targeting a newly-druggable mechanism...

Late-Breaking Clinical Trial Results Announced at VIVA 2026

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care

FCS Clinical Research Continues to Pave the Way for Breakthrough TreatmentsFORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute,...

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to...

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to...

Widex Allure AI RIC with Clarity Boost Now Available in the U.S. and Major European Countries, Redefining How AI Supports Natural Hearing

Expansion into 15 additional countries brings Widex natural sound and on-demand AI support to more wearers worldwide5x more wearers preferred Allure AI RIC with...

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

Multi-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measuresGENEVA, Oct. 14, 2026 /PRNewswire/ --...

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will...

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn’s...

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 findings in...

Mercy Medical Center Expands Prostate Cancer Treatment Options With Advanced TrueBeam Technology

BALTIMORE, Oct. 13, 2026 /PRNewswire/ -- Mercy Medical Center is expanding advanced treatment options for men with prostate cancer through the enhanced capabilities of its...

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation |...

The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001;...

Legacy Healthcare’s CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older

EPALINGES, Switzerland, Oct. 13, 2026 /PRNewswire/ -- Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U.S. Food and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy